Victoria Socha

DocwireNews

Results of previous studies have shown that sacubitril/valsartan, a new class of angiotensin receptor neprilysin inhibitor, is beneficial for patients with heart failure via blocking the degradation of natriuretic peptides and inhibition of activation of the renin-angiotensin-aldosterone system (RAAS). Those effects also relate to the pathophysiologic mechanisms of chronic kidney disease (CKD); however, according to Wei Zhou, MD, and Xinyue Yang, MD, and colleagues, the effects on CKD are unclear.The researchers performed a systematic review and meta-analysis to examine the efficacy and safety of sacubitril/valsartan for patients with CKD. Results were reported online in International Urology and Nephrology [doi.org/10.1007/s11255-023-03599-w].The search included Embase, PubMed, and the Cochrane Library. Studies of interest were randomized controlled trials comparing sacubitril/valsartan with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBS) in patients with CKD with estimated glomerular filtration rates (eGFR) below 60 mL/min/1.73 m2. Effect size was estimated using the odds ratio (OR) with 95% CI.The meta-analysis included six trials with a total of 6217 patients with CKD. Sacubitril/valsartan attenuated the risk of cardiovascular death or hospitalization for heart failure (OR, 0.68; 95% CI, 0.61-0.76; P&lt;.00001), and prevented the incidence of serum creatinine elevation in patients with CKD (OR, 0.79; 95% CI, 0.67-0.95; P=.01).Results of subgroup analysis of eGFR demonstrated that with long follow-up, sacubitril/valsartan significantly decreased the number of patients with more than 50% reduction in eGFR compared with ACEi/ARBs (OR, 0.52; 95% CI, 0.32-0.84; P=.008). In patients with CKD, sacubitril/valsartan reduced the incidence of end-stage renal disease (OR, 0.59; 95% CI, 0.29-1.20; P=.14).In analyses of safety, there was an association between sacubitril/valsartan and the occurrence of hypotension (OR, 1.71; 95% CI, 1.15-2.56; P=.008). There was no trend toward increasing the risk of hyperkalemia in patients in the sacubitril/valsartan group (OR, 1.09; 95% CI, 0.75-1.60; P=.64).In conclusion, the authors said, &ldquo;This meta-analysis indicated that sacubitril/valsartan improved renal function and conferred effective cardiovascular benefits in patients with CKD, without serious safety issues being observed. Thus, sacubitril/valsartan may be a promising option for patients with CKD. Certainly, further large-scale randomized controlled trials are needed to confirm these conclusions.&rdquo;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

No Increased Risk of Hyperkalemia for Patients Treated With Sacubitril/Valsartan

Hyperkalemia

There was no trend toward increasing the risk of hyperkalemia in patients in the sacubitril/valsartan group.

Sacubitril/valsartan for patients with CKD

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe